SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMC NEWS

TMCNET eNEWSLETTER SIGNUP

Jamieson Wellness Inc. Reports Third Quarter 2017 Financial Results
[November 09, 2017]

Jamieson Wellness Inc. Reports Third Quarter 2017 Financial Results


Jamieson Wellness Inc. ("Jamieson Wellness" or the "Company") (TSX: JWEL) today reported financial results for its third quarter and nine months ended September 30, 2017. All amounts are expressed in Canadian dollars. Certain metrics, including those expressed on an adjusted basis, are non-IFRS measures. See "Non-IFRS Financial Measures" below.

Highlights and Summary of Third Quarter 2017 Results versus Third Quarter 2016 Results

  • Revenue increased 45.0% to $80.1 million;
  • Adjusted EBITDA increased 42.9% to $16.1 million;
  • Net income was $1.1 million and Adjusted Net Income increased 210.2% to $7.8 million;
  • The Company reiterated its outlook for 2017 pro forma Adjusted EBITDA of $62 (1) million and narrowed its outlook range for 2017 pro forma revenue (1) to $303 to $307 million, including an estimated $2.0 million impact due to the translation of foreign denominated revenues into Canadian dollars.


_______________
1 Pro forma 2017 revenue and Adjusted EBITDA assumes the acquisition of Body Plus Nutritional Products Inc. ("Body Plus") and Sonoma Nutraceuticals Inc. ("Sonoma") occurred on January 1, 2017 and thus includes the estimated contribution of the acquired business for the full 12 months of fiscal 2017. On a statutory basis and excluding the pre-acquisition results for Body Plus and Sonoma, the Company expects 2017 revenue of $299 to $303 million and Adjusted EBITDA of $61.4 million.
 

"We delivered strong third quarter results, including robust revenue growth in the core Jamieson Brands segment, good performance of our recent acquisitions and favorable margin expansion," said Mark Hornick, President and Chief Executive Officer of Jamieson Wellness. "We are also excited about our newest product innovation, Cold Fighter. Cold Fighter has enjoyed a great reception from the trade and has launched in time for cold and flu season. Additionally, our market-leading quality and innovation rises to a new level with the introduction of the TRU-ID certification program. Our Jamieson herbal products have qualified for this leading-edge global 3rd party certification, which will further ensure our consumers can have continued confidence in the superior quality and purity of Jamieson's herbal ingredients."

Third Quarter 2017 Results

Revenue increased 45.0% to $80.1 million in the third quarter of 2017 from $55.3 million in the third quarter of 2016 and was driven by a 34.9% increase in Jamieson Brands revenue to $61.9 million and a 94.6% increase in Strategic Partners revenue to $18.3 million. The increase in the Jamieson Brands revenue was primarily driven by the acquisition of Body Plus and 12.2% organic growth of Jamieson Brands' domestic and international volumes. The increase in Strategic Partners revenue was driven by timing and additional volumes from strong consumer demand and the acquisition of Sonoma.

Gross profit increased 51.2% to $26.4 million in the third quarter of 2017 from $17.5 million in the third quarter of 2016 and gross profit margin increased 140 basis points to 33.0% from 31.6% in the same respective periods. The increase in the gross profit margin was primarily driven by higher volumes and improved manufacturing efficiencies in the legacy Jamieson Brands segment combined with higher inherent margins from Body Plus and Sonoma.

Selling, general and administrative expenses ("SG&A") increased 43.2% to $12.7 million in the third quarter of 2017 from $8.9 million in the third quarter of 2016. As a percentage of revenue, SG&A decreased 20 basis points to 15.9% from 16.1% in the prior year period and included $0.4 million in public company costs.

Operating income increased 53.1% to $11.3 million in the third quarter of 2017 from $7.4 million in the third quarter of 2016 and operating margin increased 80 basis points to 14.1% from 13.3% in the same respective periods.

Interest expense and other financing costs were $2.4 million in the third quarter of 2017 compared to $5.7 million in the third quarter of 2016. The change was driven by lower borrowings including discharge of the note payable to Jamieson Finco LP in the Company's recent pre-IPO reorganization and lower interest rates on the Company's new credit facility entered into in January 2017.

Net income for the third quarter of 2017 was $1.1 million compared to net income of $8.3 million in the third quarter of 2016. Net income for the third quarter of 2017 included $2.6 million of public offering costs, $2.2 million of purchase consideration recorded in other expenses, $1.7 million of accelerated options vesting included in share-based compensation, $0.3 million of amortization of fair value adjustments, and $0.3 million of other non-recurring consulting and acquisition costs. Net income in the third quarter of 2016 included a $7.5 million gain associated with a reduction in preferred share obligations.

Adjusted Net Income, which excludes all non-operating expenses, increased 210.2% to $7.8 million in the third quarter of 2017 from $2.5 million in the third quarter of 2016. The increase in Adjusted Net Income primarily reflects higher sales volumes along with increased gross profit margin, leverage on SG&A and lower interest costs.

Adjusted EBITDA increased 42.9% to $16.1 million in the third quarter of 2017 from $11.3 million in the third quarter of 2016 and Adjusted EBITDA as a percentage of revenue was 20.1%, slightly lower than 20.4% in the same respective period. The growth in Adjusted EBITDA reflects higher sales volumes coupled with increased gross profit margin and lower SG&A as a percentage of revenue.

Balance Sheet & Cash Flow

The Company generated $0.3 million of cash from operations during the first nine months of fiscal year 2017 compared to $16.6 million in the same period last year. The Company's cash and cash equivalents at September 30, 2017 were $1.2 million compared to $15.9 million on December 31, 2016. On August 22, 2017, the Company declared its first quarterly dividend of $0.08 per common share to holders of record as of September 1, 2017 and paid such dividend on September 15, 2017. The dividend payment was approximately $3.0 million in the aggregate.

 
  Nine months ended    
September 30
($ in 000's) 2017   2016

$ Change

% Change

 
Cash, beginning of period 15,881 2,325 13,556 583.1 %
Cash flows from (used in):
Operating activities 293 16,551 (16,258 ) (98.2 %)
Investing activities (85,072 ) (3,311 ) (81,761 ) (2469.4 %)
Financing activities 70,094   (5,743 ) 75,837   1320.5 %
Cash, end of period 1,196   9,822   (8,626 ) (87.8 %)
 

Outlook

The Company maintains its outlook for 2017 Adjusted EBITDA while narrowing its revenue outlook, which includes the impact of the strengthening Canadian Dollar. The Company continues to expect pro forma Adjusted EBITDA(1) of $62 million and now anticipates pro forma revenue(1) in the range of $303 to $307 million in 2017. This outlook is based on a revised forecasted CAD/USD exchange rate of $1.25 compared to our previous estimate of $1.35.

The Adjusted EBITDA outlook above excludes approximately $13.1 million of non-recurring and special expenses related to the Company's initial public offering and secondary offering.

 
1 Pro forma 2017 revenue and Adjusted EBITDA assumes the acquisition of Body Plus and Sonoma occurred on January 1, 2017 and thus includes the estimated contribution of the acquired business for the full 12 months of fiscal 2017. On a statutory basis and excluding the pre-acquisition results for Body Plus and Sonoma, the Company expects 2017 revenue of $299 to $303 million and Adjusted EBITDA of $61.4 million.
 

Consolidated Financial Statements and Management's Discussion and Analysis

The Company's unaudited condensed consolidated interim financial statements and accompanying notes as at and for the three and nine months ended September 30, 2017 and related management's discussion and analysis of financial condition and results of operation ("MD&A") are available under the Company's profile on SEDAR at www.sedar.com and on the Investor Relation's section of the Company's website at https://investors.jamiesonwellness.com.

Conference Call

Management will host a conference call to discuss the Company's third quarter 2017 results at 5:00 p.m. ET on November 9, 2017. The call can be accessed live over the telephone by dialing 1-877-425-9470 from Canada and the U.S. or 1-201-389-0878 from international locations. A replay will be available shortly after the call and can be accessed by dialing 1-844-512-2921 from Canada and the U.S. or 1-412-317-6671 from international locations. The passcode for the replay is 13672402 and it will be available until Thursday, November 23, 2017.

Interested parties may listen to a simultaneous webcast of the conference call by logging on via the Investor Relations section of the Company's website at https://investors.jamiesonwellness.com or directly at http://public.viavid.com/index.php?id=126813. A replay of the webcast will be available for approximately 30 days following the call.

About Jamieson Wellness

Jamieson Wellness is dedicated to improving the world's health and wellness with its portfolio of innovative natural health brands. Established in 1922, Jamieson Vitamins is the Company's heritage brand and Canada's #1 consumer health brand. Jamieson Wellness manufactures and markets sports nutrition products and specialty supplements under its Progressive, Precision and Iron Vegan brands. The Company also markets products by Lorna Vanderhaeghe Health Solutions (LVHS), the #1 women's natural health focused brand in Canada. For more information please visit jamiesonwellness.com.

Jamieson Wellness' head office is located at 2 St. Clair Avenue West, Toronto, Ontario, Canada.

Forward-Looking Information

This press release may contain forward-looking information within the meaning of applicable securities legislation. Such information includes, but is not limited to, statements related to the Company's anticipated growth opportunities and its outlook for its 2017 revenue and Adjusted EBITDA. Words such as "expect," "anticipate," "intend," "attempt," "may," "plan," "will", "can", "believe," "seek," "estimate," and variations of such words and similar expressions are intended to identify such forward-looking information. This information reflects the Company's current expectations regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the Company's control, that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Such risks and uncertainties include, but are not limited to, the factors discussed under "Risk Factors" in the Company's final prospectus ("Prospectus") dated June 29, 2017 in respect of its initial public offering. This information is based on the Company's reasonable assumptions and beliefs in light of the information currently available to it and the statements are made as of the date of this press release. The Company does not undertake any obligation to update such forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law or regulatory authority.

We caution that the list of risk factors and uncertainties is not exhaustive and other factors could also adversely affect the Company's results. Readers are urged to consider the risks, uncertainties and assumptions associated with these statements carefully in evaluating the forward-looking information and are cautioned not to place undue reliance on such information. See "Forward-looking Information," "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations - Outlook" in the Prospectus for a discussion of the uncertainties, risks and assumptions associated with these statements.

 

Jamieson Wellness Inc.

Unaudited Condensed Consolidated Interim Statements of Operations
In thousands of Canadian dollars, except per share data
 
  Three months ended   Nine months ended
September 30 September 30
2017   2016 2017   2016
 
Revenue 80,145 55,263 216,301 182,636
Cost of sales 53,722   37,783   142,349   125,528  
Gross profit 26,423 17,480 73,952 57,108
 
Gross profit margin 33.0 % 31.6 % 34.2 % 31.3 %
 
Selling, general and administrative expenses 12,713 8,875 39,337 33,830
Share-based compensation 2,429   1,235   4,613   3,701  
Earnings from operations 11,281 7,370 30,002 19,577
- - - -
Operating margin 14.1 % 13.3 % 13.9 % 10.7 %
 
Foreign exchange (gain) loss (203 ) (59 ) 215 (38 )
Termination benefits and related costs - 152 2,499 1,186
Public offering costs 2,636 - 9,520 -
Acquisition costs 140 - 2,443 -
Other expenses 2,506 - 6,430 30
Preferred share accretion - (7,506 ) 28,796 6,311
Interest expense and other financing costs 2,365   5,735   2,593   17,240  
Income (loss) before income taxes 3,837 9,048 (22,494 ) (5,152 )
Provision for income taxes 2,748   735   5,026   1,292  
 
Net income (loss) 1,089   8,313   (27,520 ) (6,444 )
Adjusted net income 7,793   2,512   17,833   5,809  
 
EBITDA 8,346   8,988   15,206   24,037  
Adjusted EBITDA 16,134   11,292   42,629   32,067  
 
Adjusted EBITDA margin 20.1 % 20.4 % 19.7 % 17.6 %
 
Net income (loss) 1,089 8,313 (27,520 ) (6,444 )
Preferred share dividend (9,605 ) -   (9,605 ) -  
Basic, net income (loss) attributable to common shareholders: (8,516 ) 8,313 (37,125 ) (6,444 )
 
Preferred share accretion -   (7,506 ) -   -  
 
Diluted, net income (loss) attributable to common shareholders: (8,516 ) 807   (37,125 ) (6,444 )
 
Weighted average number of shares
Basic 35,322,657 520,253 12,247,370 520,253
Diluted 35,322,657 22,917,648 12,247,370 520,253
 
Earnings per share attributable to common shareholders:
Basic, earnings (loss) per share (0.24 ) 15.98 (3.03 ) (12.39 )
Diluted, earnings (loss) per share (0.24 ) 0.04 (3.03 ) (12.39 )
 
 

Jamieson Wellness Inc.

Unaudited Condensed Consolidated Interim Statement of Financial Position
In thousands of Canadian dollars
 
  September   December
30, 2017 31, 2016
Assets
Current assets
Cash 1,196 15,881
Accounts receivable 76,893 52,888
Inventories 62,337 36,417
Prepaid expenses and other current assets 2,059   1,787  
142,485 106,973
Non-current assets
Property, plant and equipment 44,305 43,901
Goodwill 126,455 94,653
Intangible assets 205,115 157,888
Deferred income tax 2,897   1,764  
Total Assets 521,257   405,179  
 
Current liabilities
Redeemable preferred shares - 197,901
Accounts payable and accrued liabilities 67,738 51,077
Income taxes payable 4,856 2,688
Derivatives 2,081 92
Current portion of long-term debt 9,750   -  
84,425 251,758
Long-term liabilities
Long-term debt 161,753 152,777
Note to Jamieson Finco LP - 107,255
Post-retirement benefits 4,156 3,797
Deferred income tax 53,003   41,194  
Total Liabilities 303,337 556,781
Shareholders' equity (deficiency)
Share capital 234,734 400
Contributed surplus 5,725 2,598
Deficit (20,200 ) (153,724 )
Accumulated other comprehensive loss (2,339 ) (876 )
Total Shareholders' equity (deficiency) 217,920   (151,602 )
Total Liabilities and Shareholders' equity 521,257   405,179  
 
 

Jamieson Wellness Inc.

 

Segment Information

 
Jamieson Brands        
 
Three months ended
($ in 000's) September 30,
2017 2016

$ Change

% Change
 
Revenue 61,889 45,882 16,007 34.9 %

 

 

 

 

Gross profit 23,263 16,743 6,520 38.9 %
Gross profit margin 37.6 % 36.5 % - 1.1 %

 

 

 

 

Earnings from operations 9,628 7,735 1,893 24.5 %
Operating margin 15.6 % 16.9 % - (1.3 %)

 

 

 

 

Adjusted EBITDA 14,157 11,301 2,856 25.3 %
Adjusted EBITDA margin 22.9 % 24.6 % - (1.7 %)
 
 
Strategic Partners and Eliminations
 
Three months ended
($ in 000's) September 30,
2017 2016

$ Change

% Change
 
Gross Revenue 33,334 13,970 19,364 138.6 %
Less: Intercompany eliminations (15,078 ) (4,589 ) (10,489 ) (228.6 %)
Revenue 18,256 9,381 8,875 94.6 %

 

 

 

 

Gross profit 3,160 737 2,423 328.8 %
Gross profit margin 17.3 % 7.9 % - 9.4 %

 

 

 

 

Earnings from operations 1,653 (365 ) 2,018 552.9 %
Operating margin 9.1 % (3.9 %) - 13.0 %

 

 

 

 

Adjusted EBITDA 1,977 (9 ) 1,986 -
Adjusted EBITDA margin 10.8 % (0.1 %) - 10.9 %
 
 
Jamieson Brands
 
Nine months ended
($ in 000's) September 30,
2017 2016

$ Change

% Change
 
Revenue 171,456 137,308 34,148 24.9 %

 

 

 

 

Gross profit 64,452 51,595 12,857 24.9 %
Gross profit margin 37.6 % 37.6 % - -

 

 

 

 

Earnings from operations 24,863 17,514 7,349 42.0 %
Operating margin 14.5 % 12.8 % - 1.7 %

 

 

 

 

Adjusted EBITDA 36,526 28,950 7,576 26.2 %
Adjusted EBITDA margin 21.3 % 21.1 % - 0.2 %
 
 
Strategic Partners and Eliminations
 
Nine months ended
($ in 000's) September 30,
2017 2016

$ Change

% Change
 
Gross Revenue 79,846 60,720 19,126 31.5 %
Less: Intercompany eliminations (35,001 ) (15,392 ) (19,609 ) (127.4 %)
Revenue 44,845 45,328 (483 ) (1.1 %)

 

 

 

 

Gross profit 9,500 5,513 3,987 72.3 %
Gross profit margin 21.2 % 12.2 % - 9.0 %

 

 

 

 

Earnings from operations 5,139 2,063 3,076 149.1 %
Operating margin 11.5 % 4.6 % - 6.9 %

 

 

 

 

Adjusted EBITDA 6,103 3,117 2,986 95.8 %
Adjusted EBITDA margin 13.6 % 6.9 % - 6.7 %
 

Non-IFRS Financial Measures

This press release makes reference to certain non-IFRS measures. Management uses these non-IFRS financial measures for purposes of comparison to prior periods and development of future projections and earnings growth prospects. This information is also used by management to measure the profitability of ongoing operations and in analyzing the Company's business performance and trends. These measures are not recognized measures under IFRS, do not have a standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. Rather, these measures are provided as additional information to complement those IFRS measures by providing further understanding of the Company's results of operations from management's perspective. Accordingly, they should not be considered in isolation nor as a substitute for analysis of the Company's financial information reported under IFRS. We use non-IFRS measures, including "gross profit," "gross profit margin," "operating margin," "EBITDA," "Adjusted EBITDA," "Adjusted EBITDA margin," and "Adjusted Net Income" to provide supplemental measures of the Company's operating performance and thus highlight trends in the Company's core business that may not otherwise be apparent when relying solely on IFRS financial measures. Management also uses non-IFRS measures in order to prepare annual operating budgets and to determine components of management compensation. Definitions of non-IFRS measures can be found in our MD&A.

 

Reconciliation of Adjusted Net Income

 
  Three months ended   Nine months ended
September 30 September 30
($ in 000's) 2017   2016 2017   2016
 
Net income (loss) 1,089 8,313 (27,520 ) (6,444 )
Adjustments to net income (loss):
Share-based compensation 1,708 914 3,193 2,739
Amortization of fair value adjustments 282 - 1,694 -
Amortization of deferred financing fee - - 3,078 -
Foreign exchange (gain) loss (203 ) (59 ) 215 (38 )
Termination benefits and related costs - 152 2,499 1,186
Acquisition costs 140 - 2,443 -
Purchase consideration accounted for as compensation expense 2,215 - 5,906 -
Public offering costs 2,636 - 9,520 -
Net interest forgiveness - - (11,001 ) -
Preferred share accretion - (7,506 ) 28,796 6,311
Non-recurring consulting services 289 792 289 2,409
Other - 184 244 772
Related tax effects (363 ) (278 ) (1,523 ) (1,126 )
Adjusted net income 7,793   2,512   17,833   5,809  
 
 

Reconciliation of EBITDA and Adjusted EBITDA

 
  Three months ended   Nine months ended
September 30 September 30
($ in 000's) 2017   2016 2017   2016
 
Net income (loss) 1,089 8,313 (27,520 ) (6,444 )
Add:
Provision for income taxes 2,748 735 5,026 1,292
Interest expense and other financing costs 2,365 5,735 2,593 17,240
Preferred share accretion - (7,506 ) 28,796 6,311
Depreciation of property, plant, and equipment 1,283 903 3,770 3,216
Amortization of intangible assets 861   808   2,541   2,422  
- -
Earnings before interest, taxes, depreciation, and amortization (EBITDA) 8,346 8,988 15,206 24,037
Add EBITDA adjustments:
Share-based compensation 2,429 1,235 4,613 3,701
Amortization of fair value adjustments 282 - 1,694 -
Foreign exchange (gain) loss (203 ) (59 ) 215 (38 )
Termination benefits and related costs - 152 2,499 1,186
Acquisition costs 140 - 2,443 -
Purchase consideration accounted for as compensation expense 2,215 - 5,906 -
Public offering costs 2,636 - 9,520 -
Non-recurring consulting services 289 792 289 2,409
Other -   184   244   772  
Adjusted EBITDA 16,134   11,292   42,629   32,067  


[ Back To TMCnet.com's Homepage ]






Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2017 Technology Marketing Corporation. All rights reserved | Privacy Policy